Medmira (MIR) Price & Analysis

Compare

38 Followers

MIR Stock Chart & Stats

C$0.07

C$0.01(8.70%)

At close: Jan 08 4:00 PM EST

C$0.07

C$0.01(8.70%)

Day’s Range― - ―

52-Week RangeC$0.06 - C$0.13

Previous CloseN/A

Volume74.70K

Average Volume (3M)94.91K

Market Cap

C$47.72M

Enterprise ValueC$66.19M

Total Cash (Recent Filing)C$0.00

Total Debt (Recent Filing)C$17.07M

Price to Earnings (P/E)―

Beta1.31

Next Earnings

Apr 07, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding701,730,600

10 Day Avg. Volume79,718

30 Day Avg. Volume94,909

Financial Highlights & Ratios

PEG Ratio-0.35

Price to Book (P/B)-2.47

Price to Sales (P/S)232.06

P/FCF Ratio-17.70

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Proprietary Rapid-test TechnologyMedmira's proprietary rapid-test technology and point-of-care design create a durable competitive edge: low-equipment, easy-to-use diagnostics are more adoptable in clinics and low-resource settings, enabling licensing, distribution scale and barriers to entry for lesser-developed competitors.

Diversified Revenue ChannelsThe firm's mix of product sales, licensing and partnerships, plus government/NGO contracts, provides structurally diversified demand channels. This reduces reliance on a single sales route and supports steady public-health driven demand across regions, improving resilience over months.

Existing Commercial TractionAlthough small, reported TTM product revenue signals real market adoption beyond development-stage activities. Persistent sales validate product-market fit, offering a foundation for scaling, licensing or partnership-led expansion if the company secures the financing to invest in commercialization.

Bears Say

Severely Stressed Balance SheetNegative equity and high debt versus a small asset base materially elevate solvency and refinancing risk. This weak capital structure limits strategic flexibility, increases the likelihood of dilutive financing or asset sales, and constrains the company's ability to fund commercialization or withstand setbacks.

Consistent Negative Cash FlowSustained negative operating and free cash flow with worsening FCF increases dependency on external capital. This rising cash burn can force repeated financing rounds, diluting shareholders, or necessitate cost cuts that impair R&D and commercialization, hindering long-term growth prospects.

Deteriorating Margins And Weak RevenueMargins have moved from positive to sharply negative while revenue remains small and has declined, indicating deteriorating unit economics. Without clear margin recovery or significant revenue scaling, long-term sustainability is at risk and profitability may remain elusive despite operational efforts.

Medmira News

MedMira Narrows Loss as New Syphilis Test Wins Approval and MiROQ Platform Advances

Medmira ( ($TSE:MIR) ) has shared an update. MedMira reported first-quarter fiscal 2026 results marked by Health Canada...

2M ago

MedMira Inc. Reports FY2025 Financial Results and Strategic Developments

The latest announcement is out from Medmira ( ($TSE:MIR) ). MedMira Inc. reported its FY2025 financial results, highlighting...

3M ago

Health Canada Approves MedMira’s Rapid Syphilis Test Amid Rising Cases

The latest update is out from Medmira ( ($TSE:MIR) ). MedMira Inc. has received approval from Health Canada...

6M ago

MedMira Launches Clinical Trial for HIV/Syphilis Self-Test in Canada

Medmira ( ($TSE:MIR) ) has issued an announcement. MedMira has launched a clinical trial for its Multiplo® TP/HIV...

8M ago

MedMira Reports Q2 FY2025 Results, Advances in STI and HIV Testing

Medmira ( ($TSE:MIR) ) has shared an update. MedMira Inc. reported its second quarter financial results for FY2025,...

8M ago

MedMira Partners with Lovell to Enhance Federal Access to Rapid HIV Testing

Medmira ( ($TSE:MIR) ) has shared an announcement. MedMira Inc. has partnered with Lovell Government Services to expand...

10M ago

MedMira Achieves Regulatory Milestones Amidst Financial Challenges in Q2 FY2025

Medmira ( ($TSE:MIR) ) has shared an update. MedMira Inc. reported its Q2 FY2025 financial results, highlighting significant...

11M ago

MedMira Partners with MediGroup to Expand Reach in US Healthcare Market

The latest announcement is out from Medmira ( ($TSE:MIR) ). MedMira Inc. has announced a partnership with MediGroup,...

12M ago

MedMira Partners with Trimedic to Enhance Rapid Test Distribution in Canada

Medmira ( ($TSE:MIR) ) has provided an update. MedMira Inc. has announced an exclusive distribution agreement with Trimedic...

12M ago

MedMira Advances Syphilis and HIV Self-Testing in Canada

An announcement from Medmira ( ($TSE:MIR) ) is now available. MedMira Inc. has received Investigational Testing Authorizations from...

1y ago

MIR FAQ

What was Medmira Inc’s price range in the past 12 months?

Medmira Inc lowest stock price was C$0.06 and its highest was C$0.13 in the past 12 months.

What is Medmira Inc’s market cap?

Medmira Inc’s market cap is C$47.72M.

When is Medmira Inc’s upcoming earnings report date?

Medmira Inc’s upcoming earnings report date is Apr 07, 2026 which is in 43 days.

How were Medmira Inc’s earnings last quarter?

Currently, no data Available

Is Medmira Inc overvalued?

According to Wall Street analysts Medmira Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Medmira Inc pay dividends?

Medmira Inc does not currently pay dividends.

What is Medmira Inc’s EPS estimate?

Medmira Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Medmira Inc have?

Medmira Inc has 701,730,600 shares outstanding.

What happened to Medmira Inc’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Medmira Inc?

Currently, no hedge funds are holding shares in TSE:MIR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Medmira Inc

Medmira Inc. (MIR) is a Canadian biotechnology company primarily focused on the development and commercialization of rapid diagnostic tests for various infectious diseases. The company operates in the healthcare sector, specializing in point-of-care testing solutions that enable quick and accurate diagnosis of conditions such as HIV, Hepatitis, and other sexually transmitted infections. Medmira's core product offerings include its proprietary rapid test technologies, which are designed to provide reliable results with minimal equipment and training, catering to both clinical and non-clinical settings worldwide.